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Rapid eye movement (REM) sleep – characterized by vivid dreaming, motor paralysis,
and heightened neural activity – is one of the fundamental states of the mammalian
central nervous system. Initial theories of REM sleep generation posited that induction of
the state required activation of the “pontine REM sleep generator” by cholinergic inputs.
Here, we review and evaluate the evidence surrounding cholinergic involvement in REM
sleep generation. We submit that: (i) the capacity of pontine cholinergic neurotransmission
to generate REM sleep has been firmly established by gain-of-function experiments,
(ii) the function of endogenous cholinergic input to REM sleep generating sites cannot
be determined by gain-of-function experiments; rather, loss-of-function studies are
required, (iii) loss-of-function studies show that endogenous cholinergic input to the
PTF is not required for REM sleep generation, and (iv) cholinergic input to the pontine
REM sleep generating sites serve an accessory role in REM sleep generation: reinforcing
non-REM-to-REM sleep transitions making them quicker and less likely to fail.
Keywords: acetylcholine, REM sleep, pons, gain-of-function, loss-of-function, sleep dynamics, cholinomimetic
Background
Characterizing REM Sleep as a Unique State of the Central
Nervous System
Rapid eye movement (REM) sleep – characterized by vivid dreaming, electroencephalographic
activation, and motor atonia – is a fundamental operating mode of the mammalian central
nervous system. Before REM sleep was discovered, sleep was assumed to be a homogenous
brain state (1). However, electrophysiological recording of activity in the sleeping brain revealed
sleep’s dual nature (2, 3). Pioneering electroencephalography (EEG) studies showed that cortical
activity in sleeping subjects is dominated by high amplitude, low frequency oscillations; however,
beginning in the 1930s, several groups reported that, during sleep, such slow-wave activity is
periodically interrupted by periods of low-amplitude fast-waves resembling waking EEG (3–6).
The seminal characterization of this novel sleep stage and its physiological correlates were made
by Aserinsky, Kleitman, and Dement in the 1950s. They observed that periodic EEG activations
during sleep occurred together with rapid, jerky, and binocularly symmetrical eye movements,
which differed from the slow, rolling, and pendular eye movements that had been previously
described in sleeping subjects. The authors also observed other phenomena typical of the state,
including surges in respiratory rate, heightened arousal threshold, and the occurrence of “fine
movements” in the extremities (i.e., muscle twitching). Perhaps their most intriguing observation
was the association between this collection of phenomena and dreaming. Subjects awoken from
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periods of REM reported an increased incidence of highly visual
and detailed dreams.
The discovery of the REM stage of sleep presented a conceptual
challenge to the field of sleep research. Whether this stage was
a distinct sleep state, or whether all sleep stages stemmed from
a common neural mechanism was still uncertain. The distinc-
tion between these two perspectives is non-trivial. REM sleep
being a distinct state would mean that distinct neural circuitry is
responsible for its generation, circuitry giving rise to unique phys-
iology, pathophysiology, and functionality. Aserinsky, Kleitman,
andDement described the REM and non-REM sleep stages, not as
distinct states but, as different “depths” of the same biological phe-
nomenon. It was suggested that sleep cycling is a process by which
the brain progresses through deeper and deeper stages of sleep
followed by a “lightening” associated with the occurrence of EEG
activation with REMs (3). The REM sleep stage was characterized
as a “manifestation of a particular level of cortical activity which
is encountered normally during sleep” (2); that level of cortical
activity being one that is intermediate between wakefulness and
slow-wave sleep. Aserinsky, Kleitman, and Dement characterized
the activated EEG associated with REMs as being equivalent to the
electroencephalographic signature of Stage 1 sleep, which corre-
sponded to the “drowsy” stage that had been previously described
byGibbs andGibbs (7). Speaking of the Stage 1 sleep that occurs at
sleep onset, Dement and Kleitman commented that “this Stage 1
EEG seemed to be identical with those occurring later in the night
concomitant with actual eye movements” (3).
The suggestion that REM sleep represents one of the lightest
stages of sleep conflicted with data showing that arousal thresh-
old is highest during periods of REM and EEG activation (3).
Building on the descriptive work of Aserinsky, Kleitman, and
Dement, a series of experiments and philosophical arguments
(1958–1960) authored by Michel Jouvet is largely responsible for
the current conception of REM sleep as a brain state distinct
from both non-REM sleep and wakefulness (8, 9). Jouvet reported
that the occurrence of rapid cortical activity together with the
so-called “somato-vegetative phenomena” (i.e., the disappearance
of all muscle activity as well as variation in cardiac and respiratory
rhythms) persisted following various supra-pontine transections
in cats, but were eliminated following sectioning between the
pons and trapezoid bodies (8). Subsequent lesion experiments
showed that destroying portions of the pontine tegmental field
(PTF) (specifically the caudal pontine reticular formation and the
posterior part of the oral pontine reticular formation) caused a
selective loss of the REM sleep stage (8). Moreover, the REM sleep
stage could be selectively triggered by timed electrical stimula-
tion of this same region. These findings were difficult to recon-
cile with the perspective of Kleitman and colleagues that REM
sleep is an intermediary stage between wakefulness and non-
REM sleep produced by the combined action of wake and slow-
wave sleep circuitry. These data indicated that the REM sleep
stage was mechanistically unique because it depended upon the
integrity of pontine control circuitry that was not involved in
the generation of other sleep stages. Having identified a neu-
roanatomical locus for the REM sleep stage, Jouvet was able
to argue that the phenomenological components of the REM
sleep stage constituted a distinct state of the central nervous
system (8, 10–12).
A Cholinergic Mechanism of REM
Sleep Generation
Early Developments
The recognition of REM sleep as an independent sleep state led
to speculation regarding the possible mechanisms responsible for
its generation. At the CIBA Foundation symposium on the nature
of sleep in 1960, Michel Jouvet reported that the induction of
REM sleep by electrical stimulation of the PTF was followed by a
“refractory” period during which identical stimulations resulted
in wakefulness accompanied by hypertonia and agitation. He
remarked that the existence of this refractory period was sugges-
tive of a “neurohumoral mechanism [of REM sleep generation]
which would “discharge” periodically during behavioural sleep
but which could not be brought into play until a sufficient “stock”
of neurohormones was gathered.” He further speculated that this
neurohumoral mechanism may importantly involve cholinergic
neurotransmission (8). Stemming from Jouvet’s initial hypothesis,
numerous studies have investigated the potential involvement of
cholinergic neurotransmission in REM sleep generation; however,
there is presently no consensus viewpoint. This main focus of
this review will be to evaluate the evidence relating to the poten-
tial involvement of cholinergic neurotransmission in REM sleep
generation. It is our position that a consensus viewpoint can be
reached because the bulk of available evidence can be brought into
agreement when appropriately interpreted and considered in light
of recent findings.
Speculation over cholinergic involvement in the mechanism of
REM sleep generation stemmed from studies showing the REM
sleep modulating effects of systemically administered cholin-
ergic drugs (10, 11). In cats, systemic administration of the
cholinergic receptor antagonist atropine strongly disrupts sleep
and wakefulness. Systemically administered atropine results in
what was described as a “dissociation between the behaviour of
the animal and its electrical activity” (11). While the EEG of
atropinized cats was marked by slow-waves and bursting activ-
ity similar to that observed during natural sleep and anesthe-
sia, they were nevertheless awake. These animals had tonically
elevated muscle activity, adopted standing, and crouching pos-
tures, and remained responsive to auditory stimulation. How-
ever, auditory or noxious stimulation did not elicit cortical
activation. Atropinized cats did not have REM sleep. Neverthe-
less, consistent with there being some capacity of cholinergic
neurotransmission to promote REM sleep generation, increas-
ing endogenous levels of acetylcholine, by systemic admin-
istration of an acetylcholinesterase inhibitor, increased REM
sleep bout durations as well as the intensity of phasic REM
phenomena (10, 11).
Cholinergic Stimulation of the Putative REM
Sleep Generator in the Pontine Tegmental Field
Features of REM Sleep Induction by Cholinergic
Agonism in the Pontine Tegmental Field
Overview of seminal findings
The reported link between cholinergic neurotransmission and
REM sleep generation gave rise to the hypothesis that cholin-
ergic activation of the putative REM sleep generating circuitry
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in the PTF is the critical event leading to the initiation of the
state. To-date, the bulk of evidence cited in support of this
hypothesis comes from studies showing that stimulating sites in
the pons with cholinergic agonists is sufficient to induce REM
sleep. The seminal cholinergic stimulation study by George et al.
(13) showed that microinjections of cholinomimetics (i.e., car-
bachol and oxotremorine) in cats, at PTF sites where lesion-
ing eliminated REM sleep, produced extended REM sleep-like
states. These states were characterized by atonia, electrocortical
activation, reflex inactivation, and REMs. Induced REM sleep
persisted for 45–50min and occurred at a short latency fol-
lowing microinjection (1–5min). The latency to and magni-
tude of the induced REM sleep are important details because
they suggest that the PTF REM sleep circuitry is structured
such that cholinergic inputs are capable of overwhelming com-
peting influences. This “capacity to overwhelm” was the pri-
mary indicator that cholinergic neurotransmission might play
a major role in REM sleep generation. Cholinergic PTF stimu-
lation also induced dissociated states where motor atonia or a
REM sleep-like EEG theta rhythm occurred apart from other
REM sleep phenomena. The finding that dissociated states could
be triggered by acetylcholine in addition to fully orchestrated
REM sleep is significant for three reasons. First, the induc-
tion of dissociated states suggests that the PTF is a source
of multiple efferent pathways that can independently control
components of the REM sleep state. Second, the occurrence
of fully orchestrated REM sleep (i.e., marked by the synchro-
nized onset and offset of the full complement of REM sleep
components) indicates that the PTF is also a likely source of
controller/switching circuitry – responsible for coordinating the
activation of REM sleep components, while preventing the intru-
sion of other behavioral states. Finally, these findings suggest that
the phenomenological afferents and the executive controller are
cholinoceptive.
REM sleep induction by cholinergic PTF stimulation has been
repeated by numerous other studies in both cats and rats (14–
36). The experimental details of these studies are listed in Table 1.
REM sleep can be elicited by microinjection of the mixed acetyl-
choline receptor agonist carbachol, selective muscarinic acetyl-
choline receptor agonists (e.g., oxotremorine and bethanechol),
and acetylcholinesterase inhibitors (e.g., neostigmine). REM sleep
effects exhibit dose dependency and can be blocked by co-
application of cholinergic receptor antagonists (e.g., atropine).
REM sleep-like states have also been induced in decerebrate and
anesthetized animals [for a review of REM sleep induction in
reduced preparations refer to the review by Kubin (37)].
Neuroanatomy of REM sleep induction sites
Figure 1 shows the region of the PTF in which delivery of choli-
nomimetic drugs can induce REM sleep in cats (Figure 1A) and
rats (Figure 1B). Table 1 provides more specific details about the
locations of cholinomimetic drug delivery and the resulting effects
on sleep and motor behavior.
Initial studies generated disagreement regarding the location of
the pontine site(s) in the cat where cholinergic stimulation gener-
ates REM sleep. Studies by Baghdoyan et al. (21, 22) and Hobson
et al. (20) reported potent REM sleep inducing effects (40–50min
episodes and four- to ninefold increases in REM sleep time) of
cholinergic receptor agonism in the posterior portion the ventral
PTF (roughly from the posterior boundary of the laterodorsal
tegmental nucleus [LDT; P2 according to Berman (45) to the
bisection of the PTF by the facial nerve (P7) and ventral to the level
of the trigeminal motor pool]. However, lesioning studies have
showed that unlike electrolytic ablation (that destroy neurons and
axons of passage) of the ventral PTF, kainic acid (which destroy
neurons only) lesions in these regions did not affect REM sleep
or its component phenomena (46, 47). These findings suggested
that fibers passing through the ventral PTF are important for
REM sleep generation rather than the neuronal perikarya. In
contrast to posteroventral sites, REM sleep time is greatly reduced
or eliminated by chemical lesioning of the anterodorsal pontine
tegmentum (ventral to the level of the trigeminal motor pool and
anterior to P4) (48–50).
While REM sleep is induced at both anterodorsal and pos-
teroventral PTF sites, the former are associated with inducing
REM sleep at the shortest latencies following drug microinjec-
tion (i.e., <20min) (27, 29). Due to drug diffusion following
microinjection, longer latencies to REM sleep induction raise the
possibility that the site of drug action is at a distance from the
delivery site. Gnadt and Pegram (23) showed that a relatively
small volume of solution (0.1μl) containing titrated choline and
carbachol spread as much as 1–1.5mm over the course of an
hour. Similarly, Myers and Hoch (51) reported that a 0.5μl vol-
ume of radiolabeled dopamine spread 0.5–1.0mm after 15min,
while Macklis and Quattrochi (52) found that 0.050μl of radi-
olabeled carbachol spread into an area with a 4–5mm diameter
within 1 h of the microinjection. Therefore, longer latencies to
REM sleep induction following microinjection into posteroven-
tral PTF sites (injection volume range= 0.25–3μl) may be the
result of the time taken for drug to diffuse to REM sleep gen-
erating circuitry located in the anterodorsal PTF. However this
interpretation has been challenged by Reinoso-Suarez et al. (32).
They found that carbachol microinjections within the dorsal
PTF induced persistent waking states punctuated by periodic
bouts of muscle atonia, consistent with the findings of Mitler
and Dement (38) and van Dongen et al. (17). Only after sev-
eral hours of such arousal were increases in REM sleep time
observed. Moreover, they showed that carbachol microinjec-
tions in the ventral portion of the PTF strongly induced REM
sleep, with latency to induction being less than 5min on aver-
age. Garzon et al. (35) also found that REM sleep could be
induced at a short latency following ventral PTF microinjections
of carbachol.
As in cats, REM enhancing sites in the rat extend along an
anteroposterior axis from the posterior pole of the ventral tegmen-
tal nucleus of Gudden (Tv) to the root of the facial nerve (7n).
There is no particular zone within this portion of the rat PTF
where REM sleep can be reliably enhanced; responses to choliner-
gic stimulation range from no effect, to REM sleep enhancement,
to arousal and motor impairment (for details on response variety,
see the following sections and Table 1). However, despite the lack
of reliability, REM sleep enhancing sites do tend to cluster in the
subcoeruleus/sublaterodorsal portion of the rat PTFmedial to the
trigeminal motor pool (34).
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TABLE 1 | The effects of modulating pontine cholinergic neurotransmission on REM sleep.
Experiment type Reference Drug delivery Drug Species PTF region Sleep effects Motor effects Latency
Local
gain-of-function
Cordeau et al.
(14)
Microinjection Acetylcholine (20μg) Cat mPnC Injections in awake cats: induced NREM sleep
and sleep attacks; injections in sleeping cats: no
effect other than further EEG slowing; REM sleep
(“desynchronized” EEG pattern, no movement,
twitching) induced in 4 cats
1–5min
George et al.
(13)
Microinjection Carbachol (0.2–5μg);
oxotremorine (0.2–10μg)
Cat PnO/C Long bouts (45–50min) of a REM sleep-like state
(atonia, lost reflexes, “low voltage fast” EEG
pattern, “hyper-synchronous” hippocampal
activity); Mixed states: (i) atonia only, (ii) escalating
	 rhythm+ sensory responsiveness
As the REM sleep-state
waned a severe tremor
emerged
1–5min
Kostowski (15) Microinjection ACh (5–15μg); nicotine
(5μg); eserine (10μg)
Cat mPnO/C Eserine and Ach: induced signs of sedation and
sleep; Nicotine: biphasic effect, excitation
followed by sedation
Nicotine: stiffening of
the tail+ torsion of the
head
3–6min
Mitler and
Dement (38)
Microinjection Carbachol (5μg/1μl) Cat Peri-LCα/
dPNO
Induced wakefulness and arousal Motor inhibition
followed arousal (40%)
flaccidity and areflexia
lasting 20+ h
<10min
Amatruda
et al. (16)
Microinjection Carbachol (3–9μg) Cat PnO/C Persistent atonia with EEG desynchronization;
REM sleep time "3.5–4.5 times (dose dependent)
22.325.9min
van Dongen
et al. (17)
Microinjection Carbachol
(0.05–0.5μg/0.5μl)
physostigmine
(2–20μg/0.5μl)
Cat Peri-LCα/
dPNO
Carbachol: episodes of motor atonia lasting
7–19min following 60% of injections; effects
blocked by atropine but not by mecamylamine;
cats appeared awake at all times; Physostigmine:
no effects
Asymmetric body
flexion, circling,
aggression
<1–32min
van Dongen
(19)
Microinjection Carbachol
(0.05–0.5μg/0.5μl)
Cat Peri-LCα/
dPNO
Motor atonia following 30% of injections; EEG not
recorded
Asymmetric body
flexion with/without
circling (30%),
aggression (9%)
<15min
Silberman
et al. (18)
Microinjection Carbachol (4μg/0.25–1μl) Cat PnO/C REM sleep time "2–12; length "2–21 Highly variable
Hobson et al.
(20)
Microinjection Bethanechol (1.4–7μg) Cat vPnC Long bouts (40–50min) of a REM sleep-like state
(atonia, PGO waves, unresponsive,
desynchronized EEG, reversible); REM sleep time
"3–5 times (dose dependent); Mixed states:
induced at lowest dose (1.4μg), details not
specified
>25min
Baghdoyan
et al. (21)
Microinjection Neostigmine
(0.2–20μg/0.25μl)
Cat mPnO/C REM sleep time "9 (bout length and frequency
"); NREM sleep time #85%; effects were dose
dependent and were blocked by atropine
18.56.6min
Baghdoyan
et al. (22)
Microinjection Carbachol (4μg/0.5μl) Cat PnO/C REM sleep time "4 (bout length and frequency
"); NREM sleep time #85%
~45min
Gnadt and
Pegram (23)
Microinjection Carbachol
(0.1–5μg/0.1μl)
Rat PnO/C
SubC
REM sleep "1.52 only with caudal pontine
injections of 0.5 and 1.0μg doses; wake "1.5
at the 5.0μg dose while REM and NREM sleep
were reduced
Asymmetric body
flexion, "muscle tone,
circling
39min
(Continued)
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TABLE 1 | Continued
Experiment type Reference Drug delivery Drug Species PTF region Sleep effects Motor effects Latency
Shiromani (39) Microinjection Carbachol (8μg/1μl) Cat PnO/C Long bouts (11–47min) of a REM sleep-like state
(atonia, PGO waves, desynchronized EEG
pattern); Mixed states: (i) atonia only (lasting ~
50min), (ii) escalating 	 rhythm+ sensory
responsiveness
6.11.8min
Baghdoyan
et al. (26)
Microinjection ACh (5μg); carbachol
(4μg) (0.25–0.5μl)
Cat PnO/C REM sleep time "3 (bout frequency ")
(latencies# and REM sleep time" for rostrodorsal
relative to ventrocaudal injections)
4233min
Vanni-Mercier
et al. (27)
Microinjection Carbachol (0.4μg/0.2μl) Cat Peri-LCα,
PnO/C
Site-specific REM sleep effects (REM sleep
enhancement or suppression, or no effect);
peri-LCα injections were most effective: REM
sleep time "3 ("bout length (>20min) or
"frequency); NREM sleep time # independent of
site; Mixed states: (i) atonia, REMs, PGO waves,
hippocampal	 rhythm+ sensory responsiveness
(ii) atonia and hippocampal 	 rhythm only with
sensory responsiveness (iii) hippocampal 	
rhythm persisting into in NREM sleep
Peri-LCα:
5.50.9min
Velazquez-
Moctezuma
et al. (28)
Microinjection Carbachol (3.6μg/0.1μl);
McN-A-343 (M1 agonist;
1.6μg); oxotremorine (M2
agonist; 1.6μg)
Cat unknown Oxotremorine and carbachol: REM sleep time "3
and 4, respectively (bout length and frequency
effects were not reported); McN-A-343: no
response
Carb:18.1
6.4min Oxo:
NSD McN: NSD
Yamamoto
et al. (29)
Microinjection Carbachol (4μg/0.25μl) Cat Peri-LCα,
PnO
REM sleep time "0.5 on average; effect latency
and magnitude positively and negatively
correlated, respectively, with the distance of
injection sites from an oblique line running
anterodorsally to posteroventrally
1–40min
Reinoso-
Suarez et al.
(32)
Microinjection Carbachol
(0.8–16μg/0.02–0.03μl)
Cat PnO Dorsal sites: persistent wakefulness with periodic
muscle atonia; REM sleep time "2.5–3 h4 h
after injection; 5–40min REM sleep episodes;
Mixed states: atonia only; Ventral sites: REM
sleep time "6; Mixed states: PGO activity with
muscle tone and activated EEG
Dorsal:
2.21min;
ventral:
4.72.2min
Lopez-
Rodriguez
et al. (40)
Iontophoretic
microinjection
ACh (2M); neostigmine
(2M) 200–500 nA current
Cat Peri-LCα,
PnO
Induced multiple states at identical sites
depending on initial conditions. Injections during
NREM=REM sleep (39% of cases), Wake (17%),
N-Dis (12%), W-Dis (11%), no effect (22%);
Injections during Wake=REM sleep (17% of
cases), NREM (5%), N-Dis (17%), W-Dis (41%),
no effect (20%); Mixed states: desynchronized
EEG with atonia (W-Dis); synchronized EEG with
PGO waves and muscle atonia (N-Dis)
4–8min
Imeri et al. (30) Microinjection Carbachol (0.5μg/0.1μl) Rat vPnC REM sleep time "1.5; Wake and NREM sleep
were reportedly unaffected local loss-of-function
NA
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TABLE 1 | Continued
Experiment type Reference Drug delivery Drug Species PTF region Sleep effects Motor effects Latency
Mastrangelo
et al. (31)
Microinjection Carbachol (1μg/0.5μl) Rat unknown No response in 25% of rats tested; Carb induced
20–80min of wakefulness following injection; REM
sleep "1.4 thereafter (bout frequency "1.3)
Circling 60min
Bourgin et al.
(33)
Microinjection Carbachol
(1–500 ng/50 nl)
Rat PnO/C
SubC
REM sleep time "2 (bout frequency "2);
effects were dose dependent and were blocked
by atropine; highest doses induced wakefulness
NSD
Deurveilher
et al. (34)
Microinjection Carbachol
(0.005–3μg/0.1μl)
Rat PnO/C
SubC
No response (74%); carb " wakefulness (2)
(13%); often associated with motor disturbances;
REM sleep "1.5–2 (13%)
Asymmetric body
flexion (8%), circling
(3%), hypoactivity (1%)
NSD
Marks and
Birabil (36)
Microinjection Carbachol
(1.1mM/0.06μl)
Rat mPnO REM sleep time "2 and REM sleep bout
frequency "2 in 50% of injections; effects
blocked by atropine
NSD
Garzon et al.
(35)
Microinjection Carbachol
(0.04–4μg/0.02μl)
Cat vPnO Induced alternating periods of wakefulness, REM
sleep, and REM sleep-like states. REM sleep
effects were not dose dependent. REM sleep
"4–5 (bout duration and frequency "2.5).
NREM sleep was suppressed (40–100%
reduction). Mixed states: desynchronized EEG,
PGO waves, behavioral quiescence with muscle
tone (at doses >0.08μg)
5–10min
Boissard et al.
(41)
Iontophoretic
microinjection
Carbachol (100mM;
100–200 nA current)
Rat SubCA At sites where bicuculline/gabazine induced REM
sleep carbachol induced a wake-like state with
suppressed δ, 	, and σ EEG power
"muscle tone <5min
Pollock and
Mistlberger
(42)
Microinjection Neostigmine
(8.8mM/0.05μl)
Mouse PnO Induced wakefulness and suppressed NREM and
REM sleep for 3 h post injection; neostigmine
induced state characterized by “very
low-amplitude” EEG
Suppressed motor
activity, occasional
circling
Delayed by
3+ h
Grace et al.
(43)
Microdialysis Carbachol (tissue
concentration ~1.8μg/h)
Rat PnO/C
SubC
Persistent wakefulness/hyperarousal blocked by
scopolamine (1mM)
Asymmetric body
flexion, circling, high
muscle tone
NA
Local
loss-of-function
George et al.
(13)
Microinjection Atropine (1μg) – blocked
the effects of carbachol
Cat PnO/C No “visible effects” reported (no data shown) NA
Kostowski (15) Microinjection Atropine sulfate Cat mPnO/C “Caused no constant behavioral effects” (no data
shown)
NA
Gnadt and
Pegram (23)
Microinjection Atropine
(0.41μg/0.1μl) – blocked
the effects of carbachol
Rat PnO/C
SubC
No effect on REM sleep time (baseline: 8.75%
total recording time vs. atropine: 10% total
recording time)
NA
Imeri et al. (30) Microinjection Pirenzepine (M1
antagonist; 1.6μg/0.1μl);
methoctramine (M2
antagonist; 1–15μg/
0.1μl); p-F-HHSiD (M3
antagonist; 1.6μg/0.2μl)
Rat vPnC Methoctramine: "NREM sleep latency and wake
time for three highest doses; REM sleep
decreased as a% of total sleep time from ~16 to
~12% on average (across three highest doses);
pirenzepine and p-F-HHSiD: no effect
"2–6 Latency
relative to first
NREM episode
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The differences between cat and rodent studies including
wakefulness effects
There are notable differences in the features of cholinergic-
induced REM sleep between cats and rodents. Unlike in cats,
whereREMsleep episodes can be triggeredwithinminutes of drug
microinjection, reported latencies to REM sleep induction in rats
exceed 30min (Table 1). As noted previously for cats, episodes
of cholinergic-induced REM sleep can last as long as 50min and
that REM sleep time increases to levels 3–9 times normal. By
contrast, following PTF cholinergic stimulation in rats, REM sleep
time increases to only 1.5–2 times normal levels and extended
bouts of REM sleep do not occur (Table 1). Rather, increases
in REM sleep time stem from increased bout frequency. Recall
that the magnitude of REM sleep effects in cats – “the capac-
ity to overwhelm” – was the primary indicator that cholinergic
neurotransmission might play a major role in REM sleep genera-
tion. Consequently, the weaker effects of cholinergic stimulation
observed in rats have led to alternative hypotheses suggesting that
cholinergic neurotransmission in the PTF serves a modulatory,
rather than a critical, role in REM sleep generation.
In rodents, the primary effect of cholinergic stimulation is often
increased wakefulness rather than increased REM sleep (23, 33,
34, 41). Pollock andMistlberger (42) reported that microinjection
of neostigmine into the PTF of mice induces extended periods of
wakefulness characterized by elevated muscle tone, delaying REM
sleep onset for up to 3 h. Similarly, Boissard et al. (41) showed that
at dorsal PTF sites where GABAA receptor antagonism induced
REM sleep and carbachol microinjection induced a waking state
characterized by heightened muscle tone. Mastrangelo et al. (31)
showed that carbachol microinjections in the rat PTF induced
extended periods of wakefulness lasting 20–80min; thereafter,
REM sleep time increased by 40%. In a large mapping study
of the rat PTF, Deurveilher et al. (34) showed that carbachol
microinjections induced wakefulness as often as REM sleep (13%
of cases); 74% of injections produced no effect. Persistent wake-
fulness following cholinergic stimulation has also been reported
in the cat. Baghdoyan et al. (22) found that carbachol microinjec-
tions at posterodorsal PTF sites induced wakefulness marked by
ataxia, poor hind limb control, and aggressive behaviors. Mitler
and Dement (38) showed that carbachol microinjection into the
peri-locus coeruleus region of the anterodorsal PTF induced a
persistent waking state within 1–10min of injection that could last
upwards of 30 h. In that study, motor atonia did appear but only
in 6 of 15 injections after extended periods of wakefulness.
The arousing effects of cholinergic stimulation in the PTF are
often accompanied by unusual motor activity. Reporting on the
effects of carbachol microinjection into the PTF of the rat, Gnadt
and Pegram (23) noted that cholinergic stimulation sometimes
produced “ipsilateral contraction of the axial musculature, partic-
ularly in the neck and thorax. In its mildest form, this appeared
as an ipsiversive circling behavior. In its most severe form, the
contracture completely drew the rat into an incapacitating ipsi-
lateral flexion of the body.” Similar results have been reported
in cats by van Dongen (19). Reports of increased wakefulness
following delivery of cholinomimetics into the PTF are often
associated with such motor abnormalities. In the mapping study
by Deurveilher et al. (34), induced wakefulness was accompanied
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FIGURE 1 | PTF regions sensitive to cholinomimetic induction of REM
sleep. Coronal (left) and sagittal (right) maps of the cat (A) and rat (B) pons.
The shaded regions are inclusive of all the effective REM sleep inducing
injection sites from the studies listed in Table 1. Anatomical abbreviations:
5M, fifth motor nucleus; 7M, seventh motor nucleus; BC, brachium
conjunctivum; DpMe, deep mesencephalic reticular nucleus; FTC, central
tegmental field; FTG, gigantocellular tegmental field; FTM, magnocellular
tegmental field; LC, locus coeruleus; LDT, laterodorsal tegmental nucleus;
Me5, mesencephalic 5 nucleus; Peri-LCα, peri-locus coeruleus alpha; PnC,
caudal part of the pontine reticular nucleus; PnO, oral part of the pontine
reticular nucleus; PPT, pedunculopontine tegmental nucleus; PTF, pontine
tegmental field; RM, raphe magnus; RPo, raphe pontis; scp, superior
cerebellar peduncle; SubC, subcoeruleus nucleus including alpha (A), dorsal
(D), and ventral parts (V); Tv, ventral tegmental nucleus of Gudden; Tz,
nucleus of the trapezoid body. Anatomical maps were adapted from Ref.
(44, 45).
by asymmetric body flexion or hyperactive circling in 90% of
cases. The association between motor effects and arousal raises
the possibility that cholinomimetic-induced arousal is an epiphe-
nomenon of motor disruption. Therefore, particularly in rats, the
activation of motor circuitry and the resulting state of arousal
may conceal what capacity exists for cholinergic stimulation to
induce REM sleep in the PTF. It is important to acknowledge
that cholinoceptive REM sleep-related neurons in the pons are
intermingled amongst cholinoceptive locomotion-related reticu-
lospinal neurons that provide input to spinal central pattern gen-
erators (53). Experimental stimulation of these reticulospinal cells
and the mesencephalic locomotor region that drives their activity
produces similar patterns of muscle contraction and behavior as
those noted above (54).
State dissociation
In addition to the study by George et al. (13), several addi-
tional studies in cats have reported state dissociation following
cholinergic stimulation of the PTF. Cholinergic stimulation pro-
duced dissociated REM sleep states at sites scattered through-
out the PTF; however, state dissociation was associated most
frequently with microinjections in the peri-locus coeruleus
region of the anterodorsal PTF (i.e., the same region associated
with cholinomimetic-induced motor abnormalities and arousal).
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Vanni-Mercier et al. (27) reported that carbacholmicroinjection at
points near the peri-locus coeruleus alpha in cats produced several
distinct REM sleep-like states. In some cases, cats entered a state
very similar to normal REM sleep; however, hippocampal theta
activity was more reminiscent of wakefulness being described
as medium amplitude and lower frequency (i.e., 3–5Hz). This
state contrasted with periods where carbachol induced a REM
sleep-like hippocampal theta rhythm that persisted into non-REM
sleep. In other cases, cats entered a state characterized by the
occurrence of atonia, EEG desynchronization, ponto-geniculo-
occipital waves, and REMs typical of normal REM sleep; however,
the animals were otherwise alert, able to track visual stimuli, and
orient toward low intensity auditory stimuli. The most common
form of state dissociation reported in cats following cholinergic
PTF stimulation is persistent motor atonia – occurring in 80% of
studies reporting state dissociation.
Interpreting Gain-of Function Stimulation Studies
The induction of REM sleep by cholinergic stimulation of the
PTF is often regarded as indirect evidence supporting the involve-
ment of endogenous PTF cholinergic neurotransmission in REM
sleep generation. Many investigators interpret the results of gain-
of-function cholinergic stimulation studies as supporting the
same conclusions as loss-of-function experiments, just to a lesser
degree. It is our position that this should be considered a misin-
terpretation of gain-of-function stimulation studies. We submit
that, in principle, the results of such cholinergic stimulation do
not necessarily support or oppose any measure of endogenous
cholinergic involvement in REM sleep generation.
Cholinergic stimulation of the PTF tests whether or not the
endogenous cholinergic inputs to this region have a capacity,
under the conditions of the experiment, to generate REM sleep
or its component parts. In spite of the variable and species-
dependent nature of cholinergic REM sleep enhancement, the
capacity of endogenous cholinergic inputs to the PTF to generate
REM sleep has been established. However, we should not infer
the function of cholinergic PTF afferents in REM sleep generation
from their demonstrated capacity – our reasoning is as follows
(55). The function, if any, of PTF cholinergic afferents in REM
sleep generation is a product of the REM sleep control network’s
response to their input. This response depends on two factors.
The first factor is the initial state of the REM sleep control net-
work at the time of cholinergic input. The second factor is the
magnitude (and perhaps the pattern) of the cholinergic input.
Therefore, the role of PTF cholinergic afferents in REM sleep
generation is ultimately a function of the timing and the intensity
of their activation. The refractory period following carbachol-
induced REM sleep illustrates how the effect of cholinergic input
to the PTF depends on timing and initial conditions. During
the refractory period, an additional bolus of carbachol induces a
waking state marked by high muscle tone rather than REM sleep
(13). Also, optogenetic stimulation of PTF cholinergic afferents in
the LDT and pedunculopontine tegmental nucleus (PPT) is only
effective at enhancing REM sleepwhen stimulation occurs in non-
REM sleep – waking and REM sleep stimulations have no effect
[(56), see “SelectiveModulation of PPT and LDT Subpopulations”
for details]. Similar results were obtained by Lopez-Rodriguez
et al. (40) who showed that direct cholinergic stimulation in the
PTF most often induced REM sleep when microinjections were
made during non-REM sleep. Subsequent microinjections at the
same locations during wakefulness preferentially induced a disso-
ciated state characterized by motor atonia and sensory awareness.
The importance of stimulus intensity is illustrated by the fact that,
depending on the dose applied, cholinergic input to the PTF can
have no effect, induce REM sleep, induce wakefulness, or produce
dissociated states. Gain-of-function stimulation experiments sim-
ulate the effects of neural activation with intensity and timing that
are not necessarily relevant to the physiological case. The effects of
cholinomimetic stimulation of the PTF approximate the function
of endogenous cholinergic inputs only in the case that those inputs
are a major source of inductive REM sleep drive to the PTF.
However, a priori, it is equally possible that cholinergic inputs are
only minor sources of inductive drive relative to other afferents.
It is also possible that cholinergic PTF input is non-inductive;
the activation of REM sleep generating circuits in the PTF may
precede the activation of their cholinergic afferents. In either of
these alternative cases (i.e., where cholinergic PTF input is minor
or non-inductive), stimulation of the PTF with cholinomimetic
drugs could still have a major capacity to induce REM sleep
despite endogenous cholinergic input to the PTF being potentially
insignificant in the natural initiation of the state. Determining
the function of PTF cholinergic inputs in REM sleep generation
requires loss-of-function experiments that remove or block this
afferent input. This is the only approach that can preserve the
sequence of events and the initial conditions leading up to the
activation of PTF cholinergic inputs.
Case study: optogenetics and the involvement of MCH
containing neurons in REM sleep generation
There is an emerging consensus that melanin concentrating hor-
mone (MCH) containing neurons in the hypothalamus play a role
in the generation and maintenance of REM sleep. Studies report-
ing REM sleep enhancement following optogenetic stimulation of
MCH neurons are cited in support of this claim. Konadhode et al.
(57) have shown that optogenetic stimulation of MCH containing
neurons shortens sleep latency and increases time spent in both
non-REM and REM sleep at the expense of wakefulness. A similar
study by Jego et al. (58) showed that optogenetic activation of
MCH neurons during non-REM sleep facilitated non-REM-to-
REM sleep transitions, while activation at the onset of REM sleep
bouts increased their duration. Likewise, Tsunematsu et al. (59)
showed that optogenetic activation of MCH neurons induced
transitions into REM sleep and increased REM sleep time at
the expense of time spent in non-REM sleep. Many in the field
have interpreted these findings as implicating hypothalamicMCH
neurons in the mechanism of REM sleep generation (57–62). We
submit that while these data demonstrate the capacity of MCH
containing neurons to generate and maintain the state of REM
sleep, they do not necessarily implicateMCHneurons in this func-
tion. More importantly, the role of MCH containing neurons in
REM sleep generation ought to be inferred from loss-of-function
experiments rather than gain-of-function experiments. However,
neither optogenetic silencing (58) nor targeted ablation (59) of
MCH neurons has any effect on the generation or maintenance of
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REM sleep. These loss-of-function silencing experiments demon-
strate thatMCHneurons do not play a major role in the induction
ormaintenance of REM sleep, in spite of the REM sleep enhancing
effects of MCH neuron stimulation.
Blockade of Cholinergic Input to the Putative
REM Sleep Generator
Identifying the function of endogenous cholinergic inputs to the
PTF in REM sleep generation requires the removal or blockade
of cholinergic inputs. A small number of studies have examined
the effects of antagonizing cholinergic receptors in the PTF. In
the seminal study of cholinomimetic-induced REM sleep, George
et al. (13) anecdotally reported that, in two cats, atropine microin-
jections into the PTF had no “visible effects.” Similarly, Gnadt and
Pegram (23)microinjected atropine in five rats and reported that it
had no effect on REM sleep time (no data provided). Bourgin et al.
(33) reported that in three rats, microinjection of atropine alone
did not affect REM sleep time at the same sites where carbachol
induced REM sleep (no data provided). By contrast, two studies
have reported decreases in REM sleep following pharmacological
blockade of cholinergic receptors in the pons. Firstly, Shiromani
and Fishbein (24) reported significant reductions of REM sleep in
rats following pontine infusions of the muscarinic acetylcholine
receptor antagonist scopolamine. However, infusions took place
continuously over 5 days using a chronically implanted osmotic
mini-pump. Over such an extended period of time, the infused
scopolamine would have spread far beyond the target site located
in the posteromedial PTF. Similar reductions in REM sleep
occurred with medullary and ventricular infusions. In a second
study, Imeri et al. (30) reported increases in REM sleep latency in
rats following pontine microinjections of the muscarinic type-2
receptor antagonist methoctramine. Methoctramine microinjec-
tion resulted in a dose-dependent increase in the latency to REM
sleep. Total REM sleep time was also reduced following methoc-
tramine microinjections. However, the reduced REM sleep time
and the increased REM sleep latencies may have been a secondary
effect of arousal, because non-REM sleep time was also reduced
while wake time increased, particularly at the highest doses. Taken
together, these data neither confirm nor refute the involvement of
pontine cholinergic neurotransmission in the generation of REM
sleep.
In a recently published study, we aimed to determine the role
of endogenous cholinergic input to the PTF in the generation
of REM sleep in rats (63).Using bilateral reverse microdialysis
of the cholinergic receptor antagonist scopolamine, we showed
that blocking cholinergic input to the PTF had no effect on REM
sleep time or the frequency of REM sleep episodes. Importantly,
the concentration of antagonist used was sufficient to block the
effects of carbachol microperfusion (63). In our study, carbachol
mainly induced extended episodes of wakefulness marked by
abnormal motor behavior [similar to Ref. (17, 23, 34, 38)]. In the
event that cholinergic receptor antagonism in the PTF does not
block or reduce REM sleep, there is always the possibility that
drug delivery was unable to completely block cholinergic input
to the PTF. We aimed to minimize this possibility (63). Having
previously measured the extent of drug diffusion using reverse
microdialysis (43), we would expect microperfused antagonist to
permeate the cholinoceptive REM sleep induction zone of the
rat (approximately 14mm3) within the recording period. Most
importantly, we showed that scopolamine microperfusion in the
PTF effectively blocked the REM sleep enhancement produced
by selectively activating PTF cholinergic afferents in the PPT
(see “Selective Modulation of PPT and LDT Subpopulations” for
details) (63). Accordingly, we expect that our microperfusions of
scopolamine were sufficient to block the endogenous cholinergic
input to REM sleep generating sites in the PTF. Since scopolamine
microperfusion into the PTF still had no effect onREM sleep time,
we submit that endogenous cholinergic input to the PTF is not
involved in the induction of REM sleep (63). Despite not effecting
REM sleep time, antagonism of cholinergic inputs to the PTF did
increase the duration and failure rate of transitions from non-
REM-to-REM sleep (63). Therefore, while cholinergic inputs to
the PTF are not required for inducing transitions into REM sleep,
they may serve an accessory role in reinforcing transitions after
their initiation.
Cholinergic Afferents of the Pontine
Tegmental Field
Non-Selective Modulation of the PPT and LDT
The claim that cholinergic neurotransmission in the PTF plays a
major role in REM sleep generation entails that PTF cholinergic
afferents located in the PPT and LDT are principal sources of the
inductive drive that initiates REM sleep. PPT and LDT cell groups
contain subpopulations of neurons that increase their activity in
anticipation of and during REM sleep (i.e., REM sleep-active)
(64–66). The activation of cholinergic REM sleep-active PPT and
LDT neurons is likely responsible for the increase in endogenous
acetylcholine release in the PTF during REM sleep (67). Electrical
or pharmacological stimulation of PPT andLDTneurons has been
shown to increase REM sleep (66, 68–70), induce acetylcholine
release in the PTF (71), and evoke scopolamine-sensitive exci-
tatory postsynaptic potentials in PTF neurons (72). These data
further support the claim that cholinergic PTF afferents have a
capacity to generate REM sleep.
Determining the function of cholinergic PPT and LDTneurons
in REM sleep generation requires loss-of-function experiments.
Reductions inREMsleep have been reported following electrolytic
or chemical lesioning of the PPT and the LDT in cats, consistent
with their causal involvement in REM sleep generation (49, 73).
However, in these studies, lesions were not restricted to cholin-
ergic cell areas and are therefore difficult to interpret. Lesions
included other important components of the REM sleep generat-
ing circuitry, including the deep mesencephalic reticular nucleus
(DpMe), the ventrolateral periaqueductal gray (vlPAG), and the
anterodorsal PTF including the peri-locus coeruleus region.
The effects of smaller, more selective chemical lesions of the
PPT and LDT in rats (50) indicate that neither of these cell groups
is needed to generate REM sleep. Lu and colleagues reported that
LDT lesions did not affect REM sleep per se, but did increase
the number of total state transitions per hour. Surprisingly,
PPT lesions increased, rather than decreased, REM sleep time.
This finding raises the possibility that some PPT subpopulations
may function to suppress, rather than promote, REM sleep. An
inhibitory influence on REM sleep by PPT neurons is further
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supported by the finding that pharmacological inactivation of the
PPT, by GABAA receptor agonism, increases REM sleep both as a
percentage of total recording and total sleep time – i.e., indepen-
dent of concurrent changes in wakefulness (74–76). By contrast,
Petrovic et al. (77) reported no change in REM sleep amounts
following bilateral PPT lesions; however, PPT lesions resulted
in an increased number non-REM-to-REM sleep and wake-to-
REM sleep transitions. Moreover, REM sleep split into two elec-
troencephalographically distinct states (i.e., “sigma coherent” and
“theta coherent” REM sleep).
The lack of consistency between PPT/LDT modulating studies
notwithstanding, the REM sleep effects of manipulating the PPT
or LDT en masse should not be taken to reflect the function
of the REM sleep-active cholinergic neurons in these regions.
Cholinergic REM sleep-active PPT/LDT neurons are vastly out-
numbered by other cell types (78–80). The composition of the
LDT and PPT cell groups is highly heterogeneous. While the
boundaries of the PPT and LDT are defined by their cholinergic
subpopulations, 74–81% of PPT/LDT neurons are GABAergic
or glutamatergic (81). Furthermore, immunostaining for c-Fos
following REM sleep deprivation and recovery has revealed that
only a small proportion (5–15%) of PPT/LDT neurons exhibiting
heightened activity in REM sleep are cholinergic (78, 79). Much
larger proportions (50–85%) are GABAergic (78, 82, 83). More-
over, Clement et al. (84) have shown that more than 50% of LDT
neurons found to be c-Fos positive after REM sleep recovery are
glutamatergic.
REM sleep-active neurons in the PPT and LDT can be sub-
divided into two groups based on their firing rate profile across
the sleep–wake cycle (64–66, 80). First, some REM sleep-active
neurons exhibit maximal activity in REM sleep and minimal
activity in wakefulness (i.e., REM sleep-max active). Within this
group, some neurons have firing rates that increase gradually from
active wakefulness through non-REM sleep to REM sleep, while
other neurons only markedly increase their firing immediately
prior to and during REM sleep (80). Second, some REM sleep-
active neurons in the PPT and LDT discharge minimally during
non-REM sleep. Neurons of this type exhibit increased firing
during wakefulness in association with muscle activation, firing
rate deceleration in transition to non-REM sleep, and acceleration
of firing rate in transition toREMsleep (i.e., REM sleep/wake-max
active). Within this group, some neurons discharge maximally in
activewakefulnesswhile others dischargemaximally inREMsleep
(80). In addition to REM sleep-active neurons, some PPT and
LDT neurons discharge minimally in REM sleep and maximally
during active wakefulness (80).Wake-active subpopulations of the
PPT/LDT are hypothesized components of the ascending reticular
activating system that maintains wakefulness (85).
Using juxtacellular recording and labeling in the PPT and
LDT, Boucetta et al. (80) reported that these groups are neu-
rochemically diverse, consisting of cholinergic, GABAergic, and
glutamatergic cell types. Previously, cholinergic neurons in the
PPT and LDT were assumed to be both REM sleep-max active
and REM sleep/wake-max active. However, Boucetta et al. (80)
found that recorded cholinergic neurons in the LDT and PPT
were exclusively REM sleep/wake-max active. Since the sample
size was small [six neurons; LDT(5) and PPT(1)] further studies
are needed to definitively determine whether or not any REM
sleep-active cholinergic PPT/LDT neurons are REM sleep-max
active. Boucetta et al. (80) showed that the majority (4/6) of REM
sleep/wake-max active cholinergic neurons in the LDT and PPT
discharged maximally in REM sleep. On average, discharge rates
of cholinergic REM sleep/wake-max active LDT and PPT neurons
were 63 and 348% greater than those in active and quiet wake,
respectively. The existence of PPT and LDT cholinergic neurons
that discharge maximally in REM sleep (irrespective of their
activity in wakefulness) is also supported by positive immunos-
taining for c-Fos in cholinergic LDT/PPT neurons following
recovery from selective REM sleep deprivation. If REM sleep-
active cholinergic neurons in the LDT and PPT were exclusively
REM sleep/wake-max active and did not discharge at significantly
higher rates in REM sleep as compared to wakefulness, it would
be difficult to explain the observations of Maloney et al. (78)
and Verret et al. (79) that c-Fos expression increases in rebound
versus deprived conditions when the combined time spent in
wakefulness and REM sleep remains constant. Taken together,
these studies demonstrate that there are distinct subpopulations
of neurons defined by unique combinations of neurotransmitter
expression and activity profile within the PPT and LDT. These
subpopulations could be functionally distinct and therefore the
inconsistencies between studies that manipulate these subpopu-
lations en masse could be a reflection of this functional diversity.
Selective Modulation of PPT and LDT Subpopulations
Determining the functional importance of individual PPT and
LDT subpopulations requires that they be targeted selectively.
PPT and LDT cholinergic neurons selectively express receptors
for Urotensin II, a vasomodulatory peptide (86). Urotensin II has
been shown to selectively excite cholinergic PPT andLDTneurons
in vitro (87, 88). Local infusion of Urotensin II in the PPT of
rats increased the number of REM sleep episodes and the total
time spent in REM sleep both as a percentage of total recording
and total sleep time (63, 88). Urotensin II microperfusion in the
PPT also decreased non-REM-to-REM sleep transition duration
and increased non-REM-to-REM sleep transition efficiency (i.e.,
attempts to transition from non-REM to REM sleep failed less
often) (63). The effects of Urotensin II at the PPT were blocked by
simultaneous antagonism of cholinergic receptors in the PTF (63).
Consistent with the effects of selective pharmacological activation
of PPT and LDT cholinergic neurons, selective optogenetic activa-
tion of PPT and LDT cholinergic neurons increased the frequency
of REM sleep episodes as well as time spent in REM sleep, at
the expense of time spent in non-REM sleep (56). Optogenetic
stimulation increased the probability of transitioning into REM
sleep only when stimulation occurred in non-REM sleep. REM
sleep was unaffected by stimulations occurring in wakefulness
or REM sleep (56), for commentary see Ref. (55, 89). Taken
together, these gain-of-function interventions confirm that, free
of the potentially confounding effects of modulating intermingled
non-cholinergic neurons, cholinergic PPT and LDT neurons have
the capacity to enhance non-REM-to-REM sleep transitioning
and induce REM sleep. These data also show that, at least in
the case of PPT cholinergic neurons, this capacity for REM sleep
enhancement is exerted through cholinoceptive PTF neurons.
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However, we submit that these studies do not necessitate that
cholinergic LDT and PPT neurons are involved in the induction
of REM sleep. We do not know what would be the effect, if any, of
selectively inhibiting cholinergic PPT and LDT subpopulations –
e.g., optogenetic inactivation or selective neurotoxic lesioning
with Urotensin II conjugated to diphtheria toxin (90). However,
the effects of cholinergic antagonism at the PTF (see Blockade
of Cholinergic Input to the Putative REM Sleep Generator for
details) would suggest that PPT and LDT cholinergic inputs to
the PTF increase the efficiency of non-REM-to-REM sleep transi-
tioning, but are otherwise not needed for the occurrence of REM
sleep (63).
REM sleep-max active PPT and LDT neurons can be selectively
inhibited by the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)
(8-OH-DPAT), leaving the activity of REM sleep/wake-max unaf-
fected (65). Surprisingly, selective inhibition of the REM sleep-
max active subpopulation of the PPT increased REM sleep, as
a percentage of total recording and total sleep time (91). The
increase in REM sleep time stemmed from an increase in the
frequency of REM sleep episodes particularly during periods
of low REM sleep drive/propensity (91) quantified electroen-
cephalographically using amodified algorithm developed by Ben-
ington and Heller (92) and Benington et al. (93). Recall that,
based on c-Fos immunostaining following REM sleep deprivation
and recovery, PPT REM sleep-active neurons are predominately
GABAergic and glutamatergic. It is possible that, PPT subpop-
ulations exert opposing yet complementary influences of REM
sleep. Non-cholinergic REM sleep-max active PPT neurons may
function to raise the drive threshold for REM sleep induction in
order to limit REM sleep episodes to periods of high propensity.
Following the onset of a transition into REM sleep, cholinergic
PPT neuronsmay be recruited to reinforce switching and increase
the probability of transition success (63). We hypothesize that the
combined action of these PPT subpopulations may function to
reduce the sensitivity of the REM sleep switch to noise.
The REM Sleep Switch
The Reciprocal Interaction Hypothesis
Mapping the neuroanatomical network responsible for REM sleep
generation, although necessary, is insufficient for an understand-
ing of the network dynamics that actually give rise to cycling
into and out of REM sleep. In 1975, Hobson and McCarley pro-
posed the reciprocal interactionmodel: a structural/mathematical
hypothesis meant to provide an explanation for the cyclical
generation of REM sleep. This model posited that a reciprocal
interaction between REM sleep-inactive cell groups and REM
sleep-active cell groups form a pacemaker circuit that drives oscil-
lations between sleep stages (94) (Figure 2A). Aminergic neurons
in the locus coeruleus and dorsal raphe were hypothesized as
the REM sleep-inactive cells. REM sleep-active neurons in the
PTF innervating the LC were presumed to be cholinergic and
excitatory (95). The model proposed that during wakefulness
“cholinergic” PTF neurons would be inhibited by activated amin-
ergic neurons. At non-REM sleep onset, waning aminergic neuron
activity would disinhibit “cholinergic” PTF neurons. At a critical
point, the combination of this disinhibition and auto-excitation
within the “cholinergic” cell group would enable the exponential
rise in PTF neuron activity that triggers the onset of REM sleep
(96). During REM sleep, “cholinergic” PTF neurons would excite
aminergic neurons resulting in their own inactivation and the
termination of the REM sleep episode.
The reciprocal interaction model was proposed before cholin-
ergic neurons could be immunohistochemically identified. The
discovery that PTF neurons are predominately non-cholinergic
forced a revision of the model (97) (Figure 2B). REM sleep-
active cholinergic neurons in the PPT and LDT were included
as the main REM sleep promoting group (96, 98). In the revised
model, PPT and LDT cholinergic neurons triggered REM sleep
by exciting REM sleep-related non-cholinergic neurons in the
PTF. In this version of the structural model, a mutually excitatory
connection between the PTF and the PPT/LDT was responsible
for the exponential rise in PTF neuron activity at REM sleep
onset (95, 99). This pacemaker circuit was modeled mathemat-
ically using equations of the Lotka–Volterra type derived from
population models of predator–prey interactions (94). The simple
Lotka–Volterra model formed the basis for the more robust limit
cycle model, which incorporated circadianmodulation (100). The
time course of neuronal activity in the REM sleep-active and
REM sleep-inactive cell groups predicted by the mathematical
models, coincide with the actual long-term recordings of REM
sleep-active and REM sleep-inactive neurons. However, models
of this type have been criticized on the basis that they rely on the
tuning of unconstrained parameters to achieve a particular ultra-
dian period. Several lines of evidence argue against the reciprocal
interaction model as being a workable explanation for REM sleep
generation. Most notably, loss-of-function interventions targeting
the structural components of the model – the PPT, LDT, LC,
DRN, and cholinergic neurotransmission in the PRF – have little
or no effects on the occurrence of REM sleep (50, 63, 74–76, 91).
The Flip-Flop Hypothesis
More recently, it has been suggested that mutual inhibition
between REM sleep-active and REM sleep-inactive GABAergic
cell groups creates a flip-flop switch that is critical for REM sleep
generation (50, 83). Unlike a pacemaker circuit (e.g., reciprocal
interaction model), which is intrinsically capable of generating
an ultradian rhythm, a flip-flop switch is triggered by an input
signal external to the circuit. In other words, pacemaker network
models assume that the periodicity of the sleep cycle is an intrinsic
property of the circuit’s topology, whereas a flip-flop mechanism
assumes that cycling between sleep stages occurs as a response to
external demands. A flip-flop switch can convert a graded input
signal, which changes slowly over time, into a two-state output that
reduces time spent in intermediate states (i.e., bistability) (101).
In comparison with a pacemaker model, a flip-flop mechanism
can better account for (i) the occurrence of a “rebound” after
REM sleep deprivation (102–105) and (ii) the positive correlation
between the length of a REM sleep bout and the length of the pre-
ceding non-REM bout (this correlation would likely be negative
in the case of a pacemaker mechanism) (92).
In 2006, Lu and colleagues proposed that REM sleep is
generated by a mutually inhibitory interaction between REM
sleep-active GABAergic neurons in the sublaterodorsal region
of the PTF and REM sleep-inactive GABAergic neurons in the
vlPAG and the adjacent DpMe (Figure 2C). In support of this
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FIGURE 2 | Hypothesized REM sleep control circuits. (A) The original
reciprocal interaction hypothesis. (B) Modified reciprocal interaction
hypothesis. (C) Flip-flop circuit proposed by Lu et al. (50). (D) Version of
flip-flop circuit proposed by Sapin et al. (83), modified by Grace et al. (63).
Anatomical abbreviations: DpMe, deep mesencephalic reticular nucleus;
LDT, laterodorsal tegmental nucleus; PPT, pedunculopontine tegmental
nucleus; PTF, pontine tegmental field; vlPAG, ventrolateral periaqueductal
gray.
arrangement, retrograde and anterograde tracing experiments
showed that the sublaterodorsal PTF and vlPAG/DpMe neuronal
pools mutually innervate one another (50). Moreover, Boissard
et al. (106) have shown that DpMe and vlPAG projections to
the sublaterodorsal PTF are GABAergic; Lu et al. (50) have
demonstrated that half of the sublaterodorsal pontine tegmental
cells retrogradely labeled from the DpMe and vlPAG contain
GAD67 mRNA.
In contrast to sublaterodorsal PTF inactivation, which sup-
presses REM sleep, vlPAG and DpMe inactivation potently
increases REM sleep time, increasing the frequency and length
of REM sleep episodes (50, 83, 107, 108). While these effects
are consistent with those that one would expect in the case
that the sublaterodorsal PTF and vlPAG/DpMe neuronal pools
form a mutually inhibitory flip-flop switch, it has been shown
that REM sleep-active neurons in the sublaterodorsal PTF are
predominately glutamatergic rather than GABAergic (84). It is
therefore unlikely that REM sleep-active sublaterodorsal PTF
neurons form a mutually inhibitory flip-flop switch together
with vlPAG/DpMe neurons. Sapin et al. (83) alternatively pro-
posed that a mutually inhibitory flip-flop switch might be formed
between GABAergic REM sleep-inactive vlPAG/DpMe neurons
and the large number of GABAergic REM sleep-active neurons
also located in the vlPAG/DpMe (Figure 2D). In either case, acti-
vation of REM sleep-related PTF neurons and initiation of REM
sleep would result from the withdrawal of GABAergic inhibition
by REM sleep-inactive vlPAG/DpMe neurons. Consistent with
such an inductive mechanism, GABAA receptor antagonism in
the PTF terminates non-REM sleep and induces persistent REM
sleep (41, 109–111).
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Flip-flop hypotheses of REM sleep generation remain specula-
tive; however, a recent modeling study has tested the theoretical
validity of flip-flop switch involvement in the generation of the
sleep cycle. Dunmyre et al. (112) constructed a physiological
model based on coupled flip-flop oscillators for the control of
transitioning between wakefulness, non-REM and REM sleep.
With the inclusion of separate non-REM and REM sleep “homeo-
static” drives, the modeled circuit was able to faithfully reproduce
experimentally measured rodent sleep architecture under normal
and sleep-deprived conditions. Importantly, unlike previous flip-
flop models of behavioral state transitioning (113, 114), this study
does not incorporate intrinsic oscillatory capability into the neu-
ronal groups. Therefore, this study provides theoretical validation
that “homeostatically” regulated interlocking flip-flop oscillators
are sufficient to explain behavioral state transitioning.
A Hypothesis for the Structural Basis of the
Cholinergic Effects on non-REM-to-REM
Sleep Transitioning
It was previously noted that strong evidence has confirmed the
capacity of cholinergic neurotransmission in the PTF to induce
REM sleep; however, blockade of this cholinergic neurotransmis-
sion does not prevent REM sleep. Instead, we found evidence that
cholinergic input to the PTF reinforces transitions making them
quicker and less likely to fail. We also noted that the reciprocal
interaction model posits that a mutually excitatory (i.e., positive
feedback) interaction between cholinergic LDT/PPT neurons and
the PTF causes the exponential rise in PTF neuron activity in
advance of REM sleep onset. Consistent with the existence of such
a mutually excitatory positive feedback loop, (i) neuroanatomical
evidence shows that the PTF and LDT/PPT cell groups innervate
one another (115–117) and (ii) unilateral carbachol stimulation of
the PTF causes endogenous acetylcholine release in the contralat-
eral pontine tegmentum (118), possibly due to positive feedback
onto PPT/LDT neurons from cholinoceptive PTF neurons.
Given that REM sleep time and the frequency of REM sleep
bouts are both unaffected by cholinergic inputs to the PTF, it
is unlikely that this cholinergic input provides inductive drive
to trigger the activation of REM sleep-related PTF neurons. In
other words, in the sequence of events giving rise to REM sleep,
it is unlikely that PPT/LDT activation precedes PTF activation.
The available evidence is best explained in the case where the
activation of PPT/LDT cholinergic neurons is gated by activity
in the PTF, and where the PPT/LDT provides cholinergic posi-
tive feedback to PTF neurons. In this case, cholinergic receptor
antagonism could have little or no effect on REM sleep quantity
despite there being a major capacity for exogenous cholinergic
stimulation to initiate REM sleep or its component parts (see Case
Study: Optogenetics and the Involvement of MCH Containing
Neurons in REM Sleep Generation for further discussion of this
point). Consistent with this hypothesis, the increase in firing
rates of REM sleep-active GABAergic and glutamatergic neu-
rons in the pontomesencephalic tegmentum that occurs during
the non-REM to REM sleep transition period precedes that of
cholinergic LDT/PPT neurons (80).
Using computer modeling, we have shown that a positive feed-
back loop producing this sequence (i.e., PTF!PPT/LDT!PTF)
can account for the transition reinforcement produced by PTF
cholinergic neurotransmission in vivo (63) (Figure 2D). Using
the flip-flop circuit proposed by Sapin et al. (83), we showed that
varying “cholinergic” positive feedback to the “PTF” did not delay
transition onset and therefore did not affect the activation thresh-
old of the “PTF,” likely a major determinant of REM sleep quantity
in vivo. Reducing “cholinergic” positive feedback to the “PTF”
did lengthen transitions into REM sleep as observed in vivo (63).
Under conditions of reduced positive feedback, peak firing rates
of “PTF” neurons were also suppressed. Reduced firing of PTF
neurons could underlie our observation that the normal increase
in EEG theta power occurring in REM sleep was suppressed
during cholinergic receptor blockade in the PTF (63). The PTF
contains glutamatergic neurons projecting to the medial septum
and lesioning these cells eliminates theta oscillations during REM
sleep (50). Lastly, simulations showed that “cholinergic” positive
feedback dampened potentially destabilizing surges in flip-flop
switch REM-off neuron activity that could underlie transition
failure in vivo (63).
Our hypothesis that a positive feedback mechanism underlies
the function of PTF cholinergic afferents in REM sleep generation
does not necessarily require that the upstream switching element
be a flip-flop switch. However, in the case that the main switching
element is a positive feedback flip-flop circuit, our suggestion of
an accessory cholinergic positive feedback loop takes on special
significance. Note that while only a single positive feedback loop
is required to create bistability in a signaling pathway, nested
feedback loops are nevertheless common in biology. For instance,
the polarization of cell growth in yeast (119), mammalian calcium
signaling (120), and the maturation of xenopus oocytes (121)
all utilize interlocking positive feedback loops. Using multiple
interlocked feedback loops produces more reliable switches that
are rapidly inducible and resistant to extrinsic noise (122).
Conclusion
(1) The capacity of PTF cholinergic afferents to generate REM
sleep has been firmly established by gain-of-function experiments.
(2) The function of endogenous PTF cholinergic input in REM
sleep generation cannot be determined by gain-of-function exper-
iments; rather, loss-of-function studies are required. (3) Loss-of-
function studies show that endogenous cholinergic input to the
PTF is not required for REM sleep generation. (4) Cholinergic
input to the PTF serves an accessory role in REM sleep gen-
eration: reinforcing non-REM-to-REM sleep transitions making
them quicker and less likely to fail.
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